Radioactive beads with immunotherapy for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies a new combination for advanced liver cancer. You would receive tiny radioactive beads placed directly into the liver (SIRT) along with an immunotherapy medicine called atezolizumab (with or without a targeted drug called bevacizumab), to see if this helps shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a liver cancer diagnosis (called hepatocellular carcinoma) that was confirmed by a scan or biopsy.
- Your tumor is larger than 6 centimeters (about 2.4 inches).
- Your liver function is good enough (scored as Child-Pugh A or B7).
- The cancer is not eligible for treatments like surgery, ablation, transplant, or standard chemoembolization.
- The cancer has grown into a blood vessel (macrovascular invasion) or your blood test shows a high alpha-fetoprotein (AFP) level (above 100).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for liver cancer that cannot be surgically removed yet. It uses tiny radioactive beads (yttrium-90) to deliver radiation directly to the tumor, along with immunotherapy drugs and a targeted therapy to shrink the tumor, with the hope that it can later be surgically removed.
This trial studies whether combining three treatments—an immunotherapy drug (Atezo), a blood-vessel-blocking drug (Bev), and a radioactive bead treatment (SIRT-Y90)—can help patients with advanced liver cancer that cannot be surgically removed. The goal is to see if using all three together works better than using fewer treatments.
This trial tests combining radiation therapy with immunotherapy (AtezoBev) before a liver transplant for advanced liver cancer. The goal is to see if this approach can shrink tumors and make transplant possible for more people.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
Hear when a new Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.